Treatment outcome according to tumor RAS mutation status in CRYSTAL study patients with metastatic colorectal cancer (mCRC) randomized to FOLFIRI with/without cetuximab
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Disclosure Information<br />Relationships Relevant to this Session
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
CRYSTAL study design
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Background
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
RAS mutation analysis: BEAMing
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
RAS mutation analysis: BEAMing
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Study profile
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Other RAS mutations: CRYSTAL
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Other RAS mutations: first-line studies
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Comparison of RAS subgroups: <br />efficacy
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Baseline characteristics
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Progression-free survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Progression-free survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Overall survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Overall survival
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Efficacy: RAS subgroups
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Safety: grade 3/4 adverse events
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Conclusions
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Acknowledgments
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
